Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study.
angiosarcoma
breast sarcoma
radiation-induced cancers
radiation-induced sarcoma
radiotherapy
soft-tissue sarcoma
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2023
2023
Historique:
received:
06
06
2023
accepted:
01
08
2023
medline:
2
10
2023
pubmed:
2
10
2023
entrez:
2
10
2023
Statut:
epublish
Résumé
Radiation-induced sarcomas (RIS) tend to have aggressive behaviour and because of their rarity, the most appropriate management for these malignancies is uncertain. Using the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database, a national sarcoma registry, we aimed to investigate prognostic factors and outcomes for RIS. Retrospective study of RIS patients treated from 1996 to 2021 at three Canadian centres. RIS was defined as a sarcoma arising in a previously irradiated field following a 3+ year latency period, whose histology was distinct from the initially irradiated tumour. Clinicopathologic and treatment-related information was extracted from the CanSaRCC database. Overall survival (OS) was defined as the time from RIS diagnosis to death from any cause. Response rate (RR) to neoadjuvant chemotherapy (NACT) was based on physician assessment. Time-to-event analyses were estimated using the Kaplan-Meier method, with Cox regression for multivariate analysis. We considered a two-tailed One hundred seven tumours met the criteria for RIS and were divided into three subgroups: breast angiosarcoma (BAS, Surgery is standard, and NACT might be useful to downsize large lesions, especially in BAS patients. Raising RIS awareness is fundamental to promoting appropriate management and fostering research through multi-institutional collaborations.
Sections du résumé
Background
UNASSIGNED
Radiation-induced sarcomas (RIS) tend to have aggressive behaviour and because of their rarity, the most appropriate management for these malignancies is uncertain.
Objectives
UNASSIGNED
Using the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database, a national sarcoma registry, we aimed to investigate prognostic factors and outcomes for RIS.
Design
UNASSIGNED
Retrospective study of RIS patients treated from 1996 to 2021 at three Canadian centres.
Methods
UNASSIGNED
RIS was defined as a sarcoma arising in a previously irradiated field following a 3+ year latency period, whose histology was distinct from the initially irradiated tumour. Clinicopathologic and treatment-related information was extracted from the CanSaRCC database. Overall survival (OS) was defined as the time from RIS diagnosis to death from any cause. Response rate (RR) to neoadjuvant chemotherapy (NACT) was based on physician assessment. Time-to-event analyses were estimated using the Kaplan-Meier method, with Cox regression for multivariate analysis. We considered a two-tailed
Results
UNASSIGNED
One hundred seven tumours met the criteria for RIS and were divided into three subgroups: breast angiosarcoma (BAS,
Conclusion
UNASSIGNED
Surgery is standard, and NACT might be useful to downsize large lesions, especially in BAS patients. Raising RIS awareness is fundamental to promoting appropriate management and fostering research through multi-institutional collaborations.
Identifiants
pubmed: 37781501
doi: 10.1177/17588359231198943
pii: 10.1177_17588359231198943
pmc: PMC10540571
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17588359231198943Informations de copyright
© The Author(s), 2023.
Références
J Immunother Cancer. 2019 Nov 6;7(1):285
pubmed: 31694703
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Front Oncol. 2021 Jan 21;10:526360
pubmed: 33552942
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Cancer Immunol Res. 2017 Jan;5(1):84-91
pubmed: 27956380
Br J Cancer. 2013 Oct 29;109(9):2340-6
pubmed: 24104962
Int J Mol Sci. 2022 Apr 08;23(8):
pubmed: 35456944
Acta Oncol. 2008;47(8):1475-82
pubmed: 18607853
Mod Pathol. 2012 Jan;25(1):75-85
pubmed: 21909081
Oncologist. 2021 Jul;26(7):549-553
pubmed: 33594725
J Clin Oncol. 2010 Apr 20;28(12):2064-9
pubmed: 20308666
Ann Surg Oncol. 2022 Jan;29(1):533-534
pubmed: 34403005
Ann Surg Oncol. 2015 Nov;22(12):3913-20
pubmed: 25743327
JCO Precis Oncol. 2022 Oct;6:e2200087
pubmed: 36240470
Medicine (Baltimore). 2021 Mar 26;100(12):e25262
pubmed: 33761725
Am J Pathol. 2010 Jan;176(1):34-9
pubmed: 20008140
Oncologist. 2012;17(3):405-18
pubmed: 22334455
Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):425-435
pubmed: 30703514
Oncotarget. 2018 Jan 19;9(11):10042-10053
pubmed: 29515789
Oxf Med Case Reports. 2020 Jan 31;2020(1):omz138
pubmed: 32038880
Cancer Res Treat. 2018 Oct;50(4):1458-1461
pubmed: 29361819
Cancer Epidemiol. 2021 Feb;70:101857
pubmed: 33249363
Clin Oncol (R Coll Radiol). 2021 May;33(5):e232-e238
pubmed: 33386215
Ann Surg. 2004 Jun;239(6):903-9; discussion 909-10
pubmed: 15166970
Eur J Surg Oncol. 2009 Jun;35(6):654-9
pubmed: 19112005
Genes Chromosomes Cancer. 2011 Jan;50(1):25-33
pubmed: 20949568
Cancer Res Treat. 2016 Apr;48(2):650-7
pubmed: 27004955
Ann Surg Oncol. 2005 Mar;12(3):237-45
pubmed: 15827816
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33526607
J Clin Med. 2021 Feb 10;10(4):
pubmed: 33578934
Ann Surg Oncol. 2022 Jan;29(1):522-532
pubmed: 34409543